MAX BioPharma was recently selected into NIH’s Commercialization Accelerator Program (CAP). CAP is a highly competitive program that enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.

More details on CAP are found here https://sbir.nih.gov/cap.